Dyadic International, Inc. DYAI
Nov 6, 2026, 1:37 PM EST
- YTD
- -63.73%
- 1 year
- -65.21%
- Market cap
- 13.62M
- Revenue (ttm)
- 1.80M
- EPS (ttm)
- -0.23
- Shares out
- 29.59M
- Forward P/E
- -5.59
- YTD return
- -63.73%
- 1-year return
- -65.21%
- Volume
- 62.45K
- Avg volume
- 157.00K
- Open
- 0.34
- Previous close
- 0.3401
- Day's range
- 0.33 – 0.3494
- 52-week range
- 0.33 – 1.60
- Beta
- 0.72
- Price target
- 7.50 (+2100.1%)
15m -0.0574 (-14.74%)
Key statistics
- Enterprise value
- 29.07M
- PEG ratio
- 0.00
- Price / sales
- 29.36
- Price / book
- 8.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -53.90%
- Free cash flow
- -3.49M
- Total cash
- 10.10M
- Total debt
- 5.56M
- Return on equity
- -127.38%
- Short % of float
- 0.89%
- 50-day average
- 1.36
- 200-day average
- 1.48
Analyst view
- Target (low)
- 6.00
- Target (mean)
- 7.50
- Target (high)
- 9.00
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.07 | -0.01 | +0.06 | +85.71% |
| Aug 13, 2024 | Jun 1, 2024 | -0.07 | -0.07 | 0.00 | 0.00% |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.07 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | -0.07 | -0.08 | -0.01 | -14.29% |
| Nov 8, 2023 | Sep 1, 2023 | -0.06 | -0.06 | 0.00 | 0.00% |
| Aug 9, 2023 | Jun 1, 2023 | -0.05 | -0.07 | -0.02 | -40.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 24, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 3, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Jul 18, 2022 | Dawson James | down | Buy | Neutral |
About Dyadic International, Inc.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dyadic.com
News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
12 Health Care Stocks Moving In Monday's After-Market Session - 12 Health Care Stocks Moving In Wednesday's After-Market Session
Dyadic International Announces Definitive Agreements For $2.9M Registered Direct Offering And Concurrent Private Placement Of Warrants With Institutional Investor 
Dyadic International Q2 EPS $(0.06) Misses $(0.04) Estimate, Sales $961.138K Miss $993.333K Estimate 
Dyadic International Inks New Development, Commercial License Agreement With European Biotechnology Firm For Additional Precision Fermented Dairy Proteins - Dyadic International Regains Nasdaq Compliance
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
Your note
Sign in to keep a note on DYAI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOSE ARINDAM | Director | Conversion of Exercise of derivative security | Jan 2, 2024 | 27,174 |
| BUCKLAND BARRY JOHN | Director | Conversion of Exercise of derivative security | Jun 10, 2024 | 38,967 |
| EMALFARB MARK A | Chief Executive Officer | Stock Award(Grant) | Mar 12, 2024 | 4,656,950 |
| HAZELTON JOSEPH P | Officer | Stock Award(Grant) | Mar 12, 2024 | 99,168 |
| HERBST SETH J. M.D. | Director | Conversion of Exercise of derivative security | Jan 2, 2024 | 132,174 |
| KAYE JACK | Director | Conversion of Exercise of derivative security | Jan 2, 2024 | 33,581 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bandera Partners LLC | 5.87% | 1,566,908 | 2.80M | Sep 29, 2024 |
| Chapin Davis, Inc. | 3.25% | 868,301 | 1.55M | Sep 29, 2024 |
| Vanguard Group Inc | 3.02% | 805,808 | 1.44M | Sep 29, 2024 |
| Blackrock Inc. | 0.96% | 255,800 | 457.88K | Sep 29, 2024 |
| Northeast Financial Consultants Inc | 0.94% | 250,000 | 447.50K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.90% | 240,175 | 429.91K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.23% | 596,383 | 1.07M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.60% | 161,079 | 288.33K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.42% | 113,483 | 203.13K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.19% | 52,019 | 93.11K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.18% | 48,866 | 87.47K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 37,642 | 67.38K | Oct 30, 2024 |